Cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line therapy of patients with EGFR mutation-positive non-small-cell lung cancer in the United States and China

BACKGROUND: This study aimed to investigate the cost-effectiveness of dacomitinib and gefitinib for the first-line treatment of advanced non-small-cell lung cancer (NSCLC) in epidermal growth factor receptor (EGFR) mutation-positive patients from the perspective of healthcare systems in the United S...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Xinglu, Fang, Nan, Li, Huanan, Liu, Yanyan, Yang, Fan, Li, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246172/
https://www.ncbi.nlm.nih.gov/pubmed/34268373
http://dx.doi.org/10.21037/atm-20-6992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246172/
https://www.ncbi.nlm.nih.gov/pubmed/34268373
http://dx.doi.org/10.21037/atm-20-6992

Ejemplares similares